Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer Phase 3 PANOVA-3 trial showed a ...

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and ...

(RTTNews) - Novocure (NVCR) announced that the U.S. FDA has approved Optune Pax for adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel.

Novocure shares were soaring Thursday after the company said the Food and Drug Administration approved its Optune Pax product to treat people with certain pancreatic cancers. Novocure stock ended ...

Earnings call NovoCure delivered a strong Q1 2026 with net revenue of $174M, up 12% YoY, driven by international growth and the successful U.S. launch of Optune Pax for pancreatic cancer. Management ...

Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio Optune Pax approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic ...

In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...